Clinical data for all patients who had abnormal liver function tests I
| Patient ID | Age | Sex | Cancer | Regimen | Pathology | Peak ALT | Treatment | Other autoimmune effects |
| I1(_08) | 72 | M | Melanoma | Pem then Ipi (H) | Hepatitis | 706 | Prednisolone | Colitis |
| I+N1(_38) | 67 | M | Melanoma | Ipi and Niv together (H) | Hepatitis | 73 | Methylprednisolone, prednisolone, infliximab | Colitis, rash, hypoadrenalism |
| I2, P1(_07) | 76 | F | Melanoma | Ipi (H), then Pem (H) | Hepatitis | 122(I), 699(P) | Prednisolone, MMF, tacrolimus | Colitis |
| I+N2(_72) | 63 | M | Melanoma | Ipi and Niv together(H) | Hepatitis | 88 | Prednisolone | Colitis, rash |
| I+N3(_40) | 70 | M | Melanoma | Ipi and Niv together (H) | Hepatitis | 434 | Prednisolone | Colitis |
| I3(_87) | 42 | M | Melanoma | Pem then Ipi (H) | Hepatitis | 1932 | Dexamethasone, prednisolone, MMF | |
| I+N4(_59) | 43 | F | Melanoma | Ipi and Niv together (H) | Hepatitis | 152 | Prednisolone | Rash |
| I+N5(_83) | 46 | M | Melanoma | Ipi and Niv together (H) | Hepatitis | 834 | Prednisolone, MMF | |
| I4(_038) | 65 | F | Melanoma | Ipi only (H) | Hepatitis | 1635 | Prednisolone | |
| N1(_42) | 71 | M | Renal Cell | Niv only (H) | Hepatitis | 102 | No treatment | |
| P2(_91) | 61 | M | Melanoma | Pem only (H) | Hepatitis | 824 | Methylprednisolone, prednisolone | |
| I+N6(_17) | 49 | F | Melanoma | Ipi and Niv together (H) | Hepatitis | 2854 | Methylprednisolone, prednisolone, MMF, infliximab | |
| I+N7(_002) | 45 | F | Melanoma | Ipi and Niv together (H) | Hepatitis | 610 | Prednisolone, MMF | Rash, hypoadrenalism, hypothyroidism, Type 1 diabetes, mucositis |
| I+N8(_44) | 51 | M | Melanoma | Ipi and Niv together (H) | Hepatitis | 790 | Methylprednisolone, prednisolone, MMF | |
| I+N9(_834) | 21 | F | Melanoma | Ipi and Niv together (H) | Hepatitis | 422 | Methylprednisolone, prednisolone, MMF | Gastritis, pancreatitis |
| P3(_92) | 73 | M | Epithelial mesothelioma | Pem only (H) | Hepatitis | 1377 | Methylprednisolone, prednisolone | |
| CHKMT238(_97) | 71 | F | Melanoma | Blinded Niv/Ipi (H) | Hepatitis | 299 | Prednisolone, MMF | |
| I+N10(_58) | 37 | F | Melanoma | Ipi and Niv together (H) | Hepatitis | 214 | Prednisolone | Rash, hyperthyroidism |
| P4(_272) | 75 | F | Non-small cell lung | Pem only (C) | Cholangitis | 444 | Prednisolone, ursodeoxycholic acid | |
| P6(_896) | 69 | M | Non-small cell lung | Pem only (H) | Hepatitis | 132 | No treatment | Pruritus, thyrotoxicosis |
| I+N16(_077) | 29 | M | Melanoma | Ipi and Niv together (H) | Hepatitis | 1343 | Methylprednisolone, prednisolone |
(H) indicates which agent patient was on when they developed hepatitis. (C) indicates patient developed cholangiopathy. Patient IDs are indicative of which regimen patients were on when they developed colitis.
Ipi, ipilimumab (anti-CTLA-4); MMF, mycophenolate mofetil; Niv, nivolumab (anti-PD-1 antibody); P, Pem, pembrolizumab (anti-PD-1 antibody).